Unaudited Financial Results for the Quarter ended June 2025 along with Limited Review Report
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Omkar Pharmachem Ltd reported zero revenue from core operations for Q1 FY26 (quarter ended June 30, 2025), with the only income being 'Other Operating Income' of Rs 13.50 lakhs — a pattern consistent with all prior reported quarters. Total expenses rose to Rs 9.92 lakhs from Rs 8.60 lakhs in Q1 FY25, driven mainly by higher employee and other costs. Profit before tax stood at Rs 3.58 lakhs (vs Rs 4.90 lakhs in Q1 FY25), and profit after tax came in at Rs 2.66 lakhs (vs Rs 4.90 lakhs), translating to EPS of Rs 0.03 (vs Rs 0.05). The company's 'Other Equity' stands at a negative Rs (65.00) lakhs, indicating accumulated reserves are in deficit. The results were approved by the Board on August 13, 2025, and carry an unqualified limited review report from Dipal R. Shah & Co., Chartered Accountants.
The absence of any core sales revenue combined with negative reserves raises questions about the company's ongoing business activity and long-term viability, even though small profits are still being booked from non-operating income. Existing shareholders should watch for any announcement on restarting operations or restructuring, as the stock is effectively running on incidental income only.